Vemurafenib reverses immunosuppression by myeloid derived suppressor cells (Q39445924)

12 September 2017

Vemurafenib reverses immunosuppression by myeloid derived suppressor cells (English)

1 reference

12 September 2017

1 reference

2

Antje Sucker

1 reference

12 September 2017

8

Dirk Schadendorf

1 reference

12 September 2017

7

Bernd Giebel

1 reference

12 September 2017

Bastian Schilling

1

1 reference

12 September 2017

Klaus Griewank

3

1 reference

12 September 2017

Fang Zhao

4

1 reference

12 September 2017

Benjamin Weide

5

1 reference

12 September 2017

André Görgens

6

1 reference

12 September 2017

Annette Paschen

9

1 reference

12 September 2017

language of work or name

English

0 references

publication date

13 April 2013

1 reference

International Journal of Cancer

12 September 2017

1 reference

12 September 2017

133

1 reference

12 September 2017

7

1 reference

12 September 2017

1653-1663

1 reference

Human T cell responses against melanoma

12 September 2017

1 reference

Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients

21 January 2018

1 reference

Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation

21 January 2018

1 reference

Myeloid derived suppressor cells in human diseases

21 January 2018

1 reference

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity

21 January 2018

1 reference

Targeting immune suppressing myeloid-derived suppressor cells in oncology.

21 January 2018

1 reference

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

21 January 2018

1 reference

Melanoma-induced immunosuppression and its neutralization

21 January 2018

1 reference

Myeloid-derived suppressor cells: linking inflammation and cancer

21 January 2018

1 reference

Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells

21 January 2018

1 reference

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

21 January 2018

1 reference

Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties

21 January 2018

1 reference

Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes

21 January 2018

1 reference

Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy

21 January 2018

1 reference

Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines

21 January 2018

1 reference

Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma.

21 January 2018

1 reference

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

21 January 2018

1 reference

Combination of targeted therapy and immunotherapy in melanoma

21 January 2018

1 reference

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition

21 January 2018

1 reference

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis

21 January 2018

1 reference

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells

21 January 2018

1 reference

IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment model

21 January 2018

1 reference

Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology

21 January 2018

1 reference

Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer.

21 January 2018

1 reference

Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives

21 January 2018

1 reference

IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients.

21 January 2018

1 reference

Aptamer-mediated blockade of IL4Rα triggers apoptosis of MDSCs and limits tumor progression

21 January 2018

1 reference

Tumor-induced myeloid-derived suppressor cell function is independent of IFN-γ and IL-4Rα.

21 January 2018

1 reference

Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines

21 January 2018

1 reference

Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells

21 January 2018

1 reference

The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.28168

1 reference

12 September 2017

1 reference